Skip to content
lifestyle.womensconference.org
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Immuneering Corporation
Immuneering Presents Additional Data Demonstrating Atebimetinib’s Broad Potential as a Backbone for Combination Therapy in Pancreatic Cancer
November 18, 2026
Immuneering Presents Data That Supports Expanding the Clinical Evaluation of Atebimetinib to Anaplastic Thyroid Cancer
November 18, 2026
Immuneering Announces New Potentially Registrational Phase 2 Trial Evaluating Atebimetinib with Chemotherapy in Anaplastic Thyroid Cancer
November 12, 2026
Immuneering to Collaborate with Astellas on Clinical Studies of Investigational CLDN18.2 Programs in Combination with Atebimetinib for Pancreatic Cancer Patients
November 12, 2026
Immuneering Appoints Accomplished Commercial Leader Grant Bogle to Board of Directors
November 9, 2026
Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference
November 4, 2026
Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium
November 4, 2026
Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates
October 29, 2026
Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026
October 26, 2026
Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
October 2, 2026
1
2
3
Next Page
→